Skip to main content
OpenTrials
Completed

NCT Number: NCT01784848

GAstric Bypass to Treat obEse Patients With steAdy hYpertension

Phase 3, unicentric, randomized clinical trial, with allocation concealment and intention-to-treat analysis to evaluate the efficacy of videolaparoscopic Roux-en-Y Gastroplasty to decrease the prescription of antihypertensive drugs maintaining normal levels of blood pressure, decrease systemic arterial blood pressure and other risk factors for cardiovascular events compared to clinical treatments of patients with arterial hypertension.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Instituto Dante Pazzanese de Cardiologia, São Paulo, Brazil

Loading trial locations.

About this study

Randomization:

The randomization list is electronically generated through specific software. A block randomization is conducted with varying block sizes at the rate of 1:1. Confidentiality of the randomization list is ensured by the central automated randomization system, through the Internet, available 24 hours a day (ACT Clinic - Sistema de Estudos Clínicos do IEP HCor).

Blinding Scheme:

Because the study involves a surgical procedure, investigators and patients cannot be blind for treatment allocated to patients.

Roux-en-Y Gastroplasty Patients allocated to surgical treatment will be admitted to the hospital to be subjected to a Roux-en-Y gastric bypass with a biliopancreatic loop of 100cm and a alimentary limb of 150cm.

Antihypertensive Treatment:

The treatment of hypertension will be standardized for all study patients. Prescribed drugs will include preferably a renin-angiotensin blocking system drug and a calcium channels blocker, except if these are contraindicated or the patient has achieved good blood pressure control using other drugs prior to study recruitment. Other drugs can be added at discretion of the attending investigator to achieve a target blood pressure of 130 x 80 mmHg. Patients are treated individually for the other associated comorbidities. Obesity treatment in the control group includes dietary advice, motivation for the practice of physical activities, and drug treatments for diabetes and dyslipidemias if applicable.

Laboratory tests and other exams:

All patients will be subjected to the following measurements throughout the study:

  • Outpatient Blood Pressure Monitoring (ABPM)
  • Blood pressure measurements taken in doctors' offices:
  • Central pressure and associated measurements (SphygmoCor®)
  • Polysomnography
  • Anthropometry
  • Nutritional survey
  • Laboratory tests
  • Echocardiogram
  • Electrocardiogram
  • Abdominal ultrasound
  • Upper gastrointestinal endoscopy with H.pylori testing

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adults aged between 18 and 65 years old.
  • hypertension diagnosis defined as in use of at least 2 high blood pressure medication at full doses.
  • body mass index between 30,0 and 39,9 kg/m2.

Exclusion criteria

  • hypertension ≥ 180/120 mmHg;
  • cerebrovascular diseases in the last 6 months.
  • Cardiovascular diseases (myocardial infarction, angina, cardiac failure) in the last 6 months.
  • Baseline psychiatric disorders: schizophrenia, bipolar disorder, severe depression, psychosis.
  • Renal diseases: diabetic nephropathy, creatinine clearance < 30 ml/min.
  • Patients with secondary hypertension except due to the sleep apnea.
  • Advanced peripheral arterial disease
  • atrophic gastritis
  • Diabetes mellitus type 1 and type 2 with HbA1 c >7,0%
  • alcoholism or use of illicit drugs
  • smokers
  • previous laparotomy
  • severe hepatic disorders
  • Pregnancy or women not using effective contraceptive methods.
  • Recent neoplasm (< 5 years)
  • Immunosuppressant drugs
  • Unable to understanding and follow the study protocol orientations.

Treatment and study plan

Laparoscopic Roux-en-Y gastric bypass (LRYGB)

Procedure

Laparoscopic Roux-en-Y gastric bypass (LRYGB)is the one of the techniques of bariatric surgery

Clinical treatment

Other

Medical treatment aiming the control of risk factors for cardiovascular diseases (including adequate control of blood pressure), psychological assistance and dietetic advice for body weight reduction.

Primary outcomes

  1. Number of Participants With a Reduction in the Number of Anti-hypertensive Drugs Used and Maintaining Blood Pressure Below 140x90mmHg

    Time frame: 12 months

    Evaluate the efficacy of Roux-en-Y Gastric Bypass on the reduction of the number of antihypertensive drugs, maintaining a controlled blood pressure (<140x90 mmHg), in 12 months.

Secondary outcomes

  1. Efficacy of Roux-en-Y Gastroplasty to Decrease the Number of Antihypertensive Drugs.

    Time frame: 12, 24, 36, 48 and 60 months

    Evaluate the efficacy of Roux-en-Y Gastric Bypass on the reduction of the number of antihypertensive drugs, maintaining a controlled blood pressure (<140x90 mmHg).

  2. Absolute Change From Baseline in Blood Pressure Levels

    Time frame: 12, 24, 36, 48 and 60 months

    Change on systemic blood pressure assessed by ambulatory blood pressure monitoring (ABPM).

  3. Effect on Central Blood Pressure Augmentation Index and Pulse Wave Velocity

    Time frame: 12, 24, 36, 48 and 60 months

    Change on central blood pressure augmentation index and pulse wave velocity as measured by SphygmoCor device

  4. Absolute Change From Baseline on Systolic Blood Pressure

    Time frame: 12, 24, 36, 48 and 60 months

    Absolute change from baseline in systolic blood pressure

  5. Absolute Change From Baseline on Diastolic Blood Pressure

    Time frame: 12, 24, 36, 48 and 60 months

    Absolute change from baseline in diastolic blood pressure

  6. Absolute Change From Baseline on Weight Loss

    Time frame: 12, 24, 36, 48 and 60 months

    Absolute change from baseline on weight loss

  7. Absolute Change From Baseline on BMI

    Time frame: 12, 24, 36, 48 and 60 months

    Absolute change from baseline on BMI

  8. Absolute Change From Baseline on Waist Circumference

    Time frame: 12, 24, 36, 48 and 60 months

    Absolute change from baseline on waist circumference

  9. Absolute Change From Baseline on Fasting Plasm Glucose Level, HbA1c and Insulin Resistance

    Time frame: 12, 24, 36, 48 and 60 months

    Change from baseline on fasting plasm glucose level, HbA1c and insulin resistance

  10. Absolute Change From Baseline on LDL-cholesterol Level

    Time frame: 12, 24, 36, 48 and 60 months

    Absolute change from baseline on LDL-cholesterol level

  11. Absolute Change From Baseline on HDL-cholesterol Level

    Time frame: 12, 24, 36, 48 and 60 months

    Absolute change from baseline on HDL-cholesterol level

  12. Absolute Change From Baseline on Triglycerides Levels

    Time frame: 12, 24, 36, 48 and 60 months

    Absolute change from baseline on triglycerides levels

  13. Absolute Change From Baseline on Uric Acid Levels

    Time frame: 12, 24, 36, 48 and 60 months

    Absolute change from baseline on uric acid levels

  14. Absolute Change From Baseline on Ultra-sensitive CRP Levels

    Time frame: 12, 24, 36, 48 and 60 months

    Absolute change from baseline on ultra-sensitive CRP levels

  15. Absolute Change From Baseline of Cardiovascular Risk

    Time frame: 12, 24, 36, 48 and 60 months

    Absolute change from baseline of cardiovascular risk calculated by Framingham Score

  16. Change on Heart Anatomy

    Time frame: 12, 24, 36, 48 and 60 months

    Change on heart anatomy as evaluated by echocardiogram

  17. Change on Sleep Quality

    Time frame: 12, 24, 36, 48 and 60 months

    Change on sleep quality as evaluated by polysomnography

  18. Adverse Events

    Time frame: At any time during the study period

    Describe the main adverse events

Sponsors and collaborators

Lead sponsor

Hospital do Coracao

Other

Collaborators

  • Ethicon Endo-Surgery

Registry information

Official study title

Phase 3 Randomized Controlled Trial Evaluating the Effect of Laparoscopic Roux-en-Y Gastric Bypass (LRYGB) on Hypertension Medication Reduction, Blood Pressure Levels and Others Cardiovascular Risk Factors.

Acronym: GATEWAY

Important dates

Study start
2013
Primary completion
2017
Study completion
2022
First posted
Feb 6, 2013
Registry last updated
Apr 7, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.